Abstract
Targeting cancer with small molecule irreversible inhibitors of kinases represents an emerging challenge in drug discovery. Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket. The most common mechanism is the Michael reaction, that refers to the addition of a nucleophile, such as cysteine, to an α,β-unsaturated carbonyl. The nucleophile reacts at the electrophilic β-position to form an adduct; as a result the inhibitor irreversibly blocks binding of ATP to the kinase, rendering the kinase inactive. Different cysteine-reactive groups have been evaluated, an acrylamide or a substituted acrylamide moiety are the Michael acceptors of choice. There are some advantages for the irreversible kinase inhibition. These compounds are highly selective because they target a specific cysteine and only a limited number of kinases has a cysteine at the corresponding position. Another advantage is that covalent bond formation can overcome competition with the high endogenous concentration of ATP. A further motivation for designing irreversible inhibitors is their longer duration of action respect to conventional inhibitors. In fact, once bound to enzyme, these compounds do not readily dissociate and the inhibition continues even after the inhibitor leaves the circulation. Moreover, these inhibitors have the potential to overcome and prevent the emergence of acquired resistance conferred by mutations. In this review examples of irreversible inhibitors are reported, focusing on chemical structures, SAR and biological activities. The great potential of these compounds could open new and promising perspectives for a broader application of this approach
Keywords: Antitumor activity, inhibition, irreversible, kinase, Michael addition, SAR, covalent, cysteine, quinazoline, quinoline
Current Medicinal Chemistry
Title: Irreversible Protein Kinase Inhibitors
Volume: 18 Issue: 20
Author(s): L. Garuti, M. Roberti and G. Bottegoni
Affiliation:
Keywords: Antitumor activity, inhibition, irreversible, kinase, Michael addition, SAR, covalent, cysteine, quinazoline, quinoline
Abstract: Targeting cancer with small molecule irreversible inhibitors of kinases represents an emerging challenge in drug discovery. Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket. The most common mechanism is the Michael reaction, that refers to the addition of a nucleophile, such as cysteine, to an α,β-unsaturated carbonyl. The nucleophile reacts at the electrophilic β-position to form an adduct; as a result the inhibitor irreversibly blocks binding of ATP to the kinase, rendering the kinase inactive. Different cysteine-reactive groups have been evaluated, an acrylamide or a substituted acrylamide moiety are the Michael acceptors of choice. There are some advantages for the irreversible kinase inhibition. These compounds are highly selective because they target a specific cysteine and only a limited number of kinases has a cysteine at the corresponding position. Another advantage is that covalent bond formation can overcome competition with the high endogenous concentration of ATP. A further motivation for designing irreversible inhibitors is their longer duration of action respect to conventional inhibitors. In fact, once bound to enzyme, these compounds do not readily dissociate and the inhibition continues even after the inhibitor leaves the circulation. Moreover, these inhibitors have the potential to overcome and prevent the emergence of acquired resistance conferred by mutations. In this review examples of irreversible inhibitors are reported, focusing on chemical structures, SAR and biological activities. The great potential of these compounds could open new and promising perspectives for a broader application of this approach
Export Options
About this article
Cite this article as:
Garuti L., Roberti M. and Bottegoni G., Irreversible Protein Kinase Inhibitors, Current Medicinal Chemistry 2011; 18 (20) . https://dx.doi.org/10.2174/092986711796391705
DOI https://dx.doi.org/10.2174/092986711796391705 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Anti-Angiogenic Targeted Therapy in Advanced Renal Cell Carcinoma (RCC):Current Status and Future Prospects
Reviews on Recent Clinical Trials Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry A Molecular Link Between Diabetes and Breast Cancer: Therapeutic Potential of Repurposing Incretin-based Therapies for Breast Cancer
Current Cancer Drug Targets Impact of the Somatotrope Growth Hormone (GH)/Insulin-Like Growth Factor 1 (IGF-1) Axis Upon Thymus Function: Pharmacological Implications in Regeneration of Immune Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Human Aurora / Ipl1p Related Kinases
Current Genomics Specific Hemosiderin Deposition in Spleen Induced by a Low Dose of Cisplatin: Altered Iron Metabolism and Its Implication as an Acute Hemosiderin Formation Model
Current Drug Metabolism Patents in miRNAs Biomarkers for Gastrointestinal Cancer Diagnostics
Recent Patents on Biomarkers Peroxisome Proliferator-Activated Receptors: The Nutritionally Controlled Molecular Networks that Integrate Inflammation, Immunity and Metabolism
Current Nutrition & Food Science Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Diabetic CVD – Focus on Vitamin D
Cardiovascular & Hematological Agents in Medicinal Chemistry PARP Inhibitors: An Interesting Pathway also for Non-Small Cell Lung Cancer?
Current Pharmaceutical Design Editorial [ Neuropeptide Y Receptors as Targets in Drug Discovery Guest Editor: Ambikaipakan Balasubramaniam ]
Current Topics in Medicinal Chemistry New Insights into the Biology of 1-Antitrypsin and its Role in Chronic Obstructive Pulmonary Disease
Current Respiratory Medicine Reviews Free Radicals and Antioxidants: How to Reestablish Redox Homeostasis in Chronic Diseases?
Current Medicinal Chemistry Function and Regulation of Tumor Necrosis Factor Receptor Type 2
Current Medicinal Chemistry Radiation Oncology and Molecular-Targeted Therapy for EGFR and its Signal Transduction Pathways: Molecular Basis and Clinical Application for Improvement of Radiotherapeutic Outcomes
Current Signal Transduction Therapy The Inverse Relationship Between Cancer and Alzheimer's Disease: A Possible Mechanism
Current Alzheimer Research Liposomal Irinotecan in the Treatment of Refractory Pancreatic Cancer
Recent Patents on Anti-Cancer Drug Discovery Micro-/Nano-Scale Biointerfaces, Mechanical Coupling and Cancer Therapy
Current Topics in Medicinal Chemistry Floating Drug Delivery Systems for Prolonging Gastric Residence Time: A Review
Current Drug Delivery